A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer - Trial NCT06108726
Access comprehensive clinical trial information for NCT06108726 through Pure Global AI's free database. This Phase 2 trial is sponsored by Northern Jiangsu Province People's Hospital and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 16 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Northern Jiangsu Province People's Hospital
Timeline & Enrollment
Phase 2
Oct 18, 2023
Oct 18, 2025
Primary Outcome
Overall Survival(OS),Objective Response Rate(ORR),Progression free survival(PFS)
Summary
The aim of this single-arm, exploratory clinical study is to evaluate the safety and efficacy
 of local injection of envafolimab combined with chemotherapy in the first-line treatment of
 non-small cell lung cancer (NSCLC) patients, and to observe the changes of immune cells in
 the local immune microenvironment before and after immunotherapy, in order to find new
 indicators for immunotherapy evaluation.
Data Source
ClinicalTrials.gov
NCT06108726
Non-Device Trial